| Autor: |
Sarkar A, Omar S; Medical Division, Weill Cornell Medicine-Qatar, Doha, Qatar., Alshareef A; Medical Division, Weill Cornell Medicine-Qatar, Doha, Qatar., Fanous K; Medical Division, Weill Cornell Medicine-Qatar, Doha, Qatar., Sarker S; Medical Division, Weill Cornell Medicine-Qatar, Doha, Qatar., Alroobi H; Medical Division, Weill Cornell Medicine-Qatar, Doha, Qatar., Zamir F; Premedical Division, Weill Cornell Medicine-Qatar, Doha, Qatar., Yousef M; Premedical Division, Weill Cornell Medicine-Qatar, Doha, Qatar., Zakaria D; Premedical Division, Weill Cornell Medicine-Qatar, Doha, Qatar. |
| Abstrakt: |
The Omicron variant of SARS-CoV-2 was detected in October 2021 and exhibited high transmissibility, immune evasion, and reduced severity when compared to the earlier variants. The lesser vaccine effectiveness against Omicron and its reduced severity created vaccination hesitancy among the public. This review compiled data reporting the relative prevalence of Omicron as compared to the early variants to give an insight into the existing variants, which may shape the decisions regarding the targets of the newly developed vaccines. Complied data revealed more than 90% prevalence within the infected cohorts in some countries. The BA.1 subvariant predominated over the BA.2 during the early stages of the Omicron wave. Moreover, BA.4/BA.5 subvariants were detected in South Africa, USA and Italy between October 2021 and April 2022. It is therefore important to develop vaccines that protect against Omicron as well as the early variants, which are known to cause more severe complications. |
